Generation Bio Co
Company Profile
Business description
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
Contact
301 Binney Street
CambridgeMA02142
USAT: +1 617 655-7500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
115
Stocks News & Analysis
stocks
A collection of our best stock opportunities
stocks
Morningstar analyst reacts to Macquarie Group’s earnings
stocks
Undervalued ASX share showing progress in global efforts
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,966.70 | 3.20 | 0.04% |
CAC 40 | 7,857.36 | 56.48 | 0.72% |
DAX 40 | 24,217.37 | 247.01 | 1.03% |
Dow JONES (US) | 44,633.23 | 204.33 | -0.46% |
FTSE 100 | 9,136.32 | 54.88 | 0.60% |
HKSE | 25,524.45 | 37.68 | -0.15% |
NASDAQ | 21,145.48 | 33.11 | -0.16% |
Nikkei 225 | 40,674.55 | 323.72 | -0.79% |
NZX 50 Index | 12,936.41 | 25.67 | 0.20% |
S&P 500 | 6,376.72 | 13.05 | -0.20% |
S&P/ASX 200 | 8,704.60 | 6.90 | 0.08% |
SSE Composite Index | 3,609.71 | 11.77 | 0.33% |